BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a sell rating to a hold rating in a research note published on Thursday.

Several other analysts also recently issued reports on the stock. ValuEngine downgraded shares of Progenics Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, September 13th. Needham & Company LLC downgraded shares of Progenics Pharmaceuticals from a strong-buy rating to a buy rating and decreased their price objective for the stock from $16.00 to $12.00 in a research note on Thursday, September 13th. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, September 11th. Finally, Jefferies Financial Group reissued a buy rating and issued a $13.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, August 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of Buy and an average price target of $11.69.

Shares of NASDAQ PGNX opened at $6.41 on Thursday. The company has a current ratio of 6.34, a quick ratio of 6.34 and a debt-to-equity ratio of 0.68. Progenics Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $9.42.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.02). The firm had revenue of $3.88 million during the quarter, compared to the consensus estimate of $3.30 million. Progenics Pharmaceuticals had a negative return on equity of 94.45% and a negative net margin of 341.41%. research analysts anticipate that Progenics Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. AJ Wealth Strategies LLC purchased a new position in shares of Progenics Pharmaceuticals during the second quarter worth approximately $113,000. Clinton Group Inc. purchased a new position in shares of Progenics Pharmaceuticals during the second quarter worth approximately $121,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Progenics Pharmaceuticals during the second quarter worth approximately $125,000. NumerixS Investment Technologies Inc increased its position in shares of Progenics Pharmaceuticals by 163.3% during the second quarter. NumerixS Investment Technologies Inc now owns 15,800 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 9,800 shares during the period. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Progenics Pharmaceuticals during the second quarter worth approximately $160,000. 88.74% of the stock is currently owned by institutional investors and hedge funds.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Featured Article: Do You Need a Fiduciary?

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.